Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Metformin is considered to be one of the most effective therapeutics for the treatment of type 2 diabetes (T2D) since it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain, or posing a risk of hypoglycemia(1,2). For over half a century, this agent...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Madiraju, Anila K., Erion, Derek M., Rahimi, Yasmeen, Zhang, Xian-Man, Braddock, Demetrios, Albright, Ronald A., Prigaro, Brett J., Wood, John L., Bhanot, Sanjay, MacDonald, Michael J., Jurczak, Michael, Camporez, Joao-Paulo, Lee, Hui-Young, Cline, Gary W., Samuel, Varman T., Kibbey, Richard G., Shulman, Gerald I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4074244/
https://ncbi.nlm.nih.gov/pubmed/24847880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature13270
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak